Descargar la presentación
La descarga está en progreso. Por favor, espere
1
European Journal of Cancer
Gemcitabine–erlotinib versus gemcitabine–erlotinib–capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group Antonio Irigoyen, Javier Gallego, Carmen Guillén Ponce, Ruth Vera, Vega Iranzo, Inmaculada Ales, Sara Arévalo, Aleydis Pisa, Marta Martín, Antonieta Salud, Esther Falcó, Alberto Sáenz, José Luis Manzano Mozo, Gema Pulido, Joaquina Martínez Galán, Roberto Pazo- Cid, Fernando Rivera, Teresa García García, Olbia Serra, Eva Ma Fernández Parra, Alicia Hurtado, Ma José Gómez Reina, Luis Jesús López Gomez, Esther Martínez Ortega, Manuel Benavides, Enrique Aranda European Journal of Cancer Volume 75, Pages (April 2017) DOI: /j.ejca Copyright © 2017 Elsevier Ltd Terms and Conditions
2
Fig. 1 Consort study flow diagram.
European Journal of Cancer , 73-82DOI: ( /j.ejca ) Copyright © 2017 Elsevier Ltd Terms and Conditions
3
Fig. 2 Progression-free survival (A) and overall survival (B) in the ITT population. European Journal of Cancer , 73-82DOI: ( /j.ejca ) Copyright © 2017 Elsevier Ltd Terms and Conditions
4
Fig. 3 Survival according to skin rash in the ITT population: A) Progression-free survival; B) overall survival. European Journal of Cancer , 73-82DOI: ( /j.ejca ) Copyright © 2017 Elsevier Ltd Terms and Conditions
5
Fig. 4 Survival according to treatment arm and skin toxicity.
European Journal of Cancer , 73-82DOI: ( /j.ejca ) Copyright © 2017 Elsevier Ltd Terms and Conditions
Presentaciones similares
© 2024 SlidePlayer.es Inc.
All rights reserved.